ViiV Healthcare, the HIV specialist majority owned by GSK, has announced week 96 and end of study results from the Phase I/II IMPAACT 2017 study, the first trial to evaluate a complete injectable long ...
Japan’s Astellas Pharma and USA-based Vir Biotechnology have entered into a global strategic collaboration to advance VIR-5500, an investigational PRO-XTEN dual-masked CD3 T-cell engager (TCE) ...
Privately-held US firm Abcuro has announced topline results from the Phase II/III MUSCLE study of ulviprubart (ABC008).
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of Eylea (aflibercept 8mg, 114.3 ...
A UK-listed biotechnology company developing inhaled and targeted delivery technologies intended to improve the performance ...
Denmark’s Novo Nordisk has announced—effective January 1, 2027—a lower $675 US list price, or wholesale acquisition cost (WAC), for Wegovy (semaglutide) injection 2.4mg and tablets 25mg, Ozempic ...
Latin American specialty pharma company SteinCares has signed a licensing agreement with India’s Shilpa Biologicals to commercialize a biosimilar across Latin America, marking the Indian group’s first ...
US pharma major AbbVie’s $100 billion agreement with the US administration signals a structural recalibration of drug pricing negotiations, tying tariff exemptions and pricing flexibility directly to ...
US biotech Generate Biomedicines has set terms for a proposed Nasdaq listing that could raise up to $425 million, as it moves to finance two Phase III asthma trials for its lead antibody. The company ...
US pharma giant Pfizer (NYSE: PFE) has struck a commercialization deal with China’s Sciwind Biosciences for the GLP-1 drug Xianyida (ecnoglutide), gaining exclusive rights in mainland China in a pact ...
US biotech Slate Medicines has launched with $130 million in series A funding to advance an experimental migraine antibody licensed from China-based DartsBio Pharmaceuticals into the clinic next year.
The US Food and Drug Administration (FDA) has granted full approval to pharma giant Pfizer’s Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and fluorouracil-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results